Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyowa Hakko President Sets Goals To Overtake Genentech

This article was originally published in PharmAsia News

Executive Summary

At a Tokyo press briefing, Kyowa Hakko President Yuzuru Matsuda disclosed that he and John Maraganore, CEO of American company Alnylam Pharmaceuticals, had made a bet to see which company would first overtake Genentech. Matsuda also stated that Kyowa will be able to achieve similar growth enjoyed by Genentech and Amgen if it utilizes its advantage in antibody technology. Commenting on RNAi drug development, in which Kyowa and Alnylam formed an exclusive alliance to develop and commercialize the RNAi therapeutic drug ALN-RSV01, Matsuda said Kyowa has to keep a venture enterprise spirit and develop two fronts in both antibody and RNAi. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts